These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8381181)

  • 1. Roundtable discussion: management issues in didanosine therapy.
    Carr A; Penny R
    J Acquir Immune Defic Syndr (1988); 1993; 6 Suppl 1():S51-5. PubMed ID: 8381181
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program.
    Montaner JS; Rachlis A; Beaulieu R; Gill J; Schlech W; Phillips P; Auclair C; Boulerice F; Schindzielorz A; Smaldone L
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):924-30. PubMed ID: 7519674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent therapy.
    Volberding PA
    J Acquir Immune Defic Syndr (1988); 1994 May; 7(5):454-6. PubMed ID: 8158538
    [No Abstract]   [Full Text] [Related]  

  • 4. Didanosine once daily: potential for expanded use.
    Pollard RB
    AIDS; 2000 Nov; 14(16):2421-8. PubMed ID: 11101051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current developments in antiviral chemotherapy. Part 4: Foscarnet, zidovudine, didanosine].
    Stamminger T; Fleckenstein B
    Fortschr Med; 1994 May; 112(13):190-1. PubMed ID: 8020860
    [No Abstract]   [Full Text] [Related]  

  • 6. [Didanosine].
    Enferm Infecc Microbiol Clin; 1995 Oct; 13(8):487-90. PubMed ID: 8555311
    [No Abstract]   [Full Text] [Related]  

  • 7. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
    Moore RD; Keruly JC; Chaisson RE
    AIDS; 2001 Mar; 15(5):617-20. PubMed ID: 11316999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection.
    Simonelli C; Comar M; Zanussi S; De Paoli P; Tirelli U; Giacca M
    AIDS; 1997 Aug; 11(10):1299-300. PubMed ID: 9256953
    [No Abstract]   [Full Text] [Related]  

  • 9. Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection. The Alter Study. Nordic HIV Therapy Group.
    Gerstoft J; Melander H; Bruun JN; Pedersen C; Głtzsche PC; Berglund O; Mathiesen L; Skinhłj P; Norrby SR
    Scand J Infect Dis; 1997; 29(2):121-8. PubMed ID: 9181646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D4T nucleoside combinations for HIV.
    Pollard RB
    Antiviral Res; 1996 Jan; 29(1):101-4. PubMed ID: 8721558
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued zidovudine or didanosine for human immunodeficiency virus infection.
    Behrman RE; Kammerman LA; Feigal DW
    N Engl J Med; 1992 Nov; 327(22):1598-9. PubMed ID: 1435893
    [No Abstract]   [Full Text] [Related]  

  • 13. Unexpected drug interactions and adverse events with antiretroviral drugs.
    Moyle G; Boffito M
    Lancet; 2004 Jul 3-9; 364(9428):8-10. PubMed ID: 15234836
    [No Abstract]   [Full Text] [Related]  

  • 14. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
    Rathbun RC; Martin ES
    Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance of a triple combination therapy with zidovudine, didanosine and interferon-alpha in seven HIV-infected patients.
    Bissuel F; Trabaud MA; Leriche K; Cotte L; Schlienger I; Rougier P; Trepo C
    AIDS; 1995 Nov; 9(11):1285. PubMed ID: 8561983
    [No Abstract]   [Full Text] [Related]  

  • 16. [HIV infection--current possibilities in antiviral therapy].
    Hirschel B
    Ther Umsch; 1994 Aug; 51(8):545-50. PubMed ID: 7940411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of HIV disease in 1993/1994.
    Fischl MA
    AIDS Clin Rev; 1993-1994; ():167-87. PubMed ID: 8217898
    [No Abstract]   [Full Text] [Related]  

  • 18. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
    Bozzette SA; Kanouse DE; Duan N; Berry S; Richman DD
    Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection.
    Cepeda JA; Wilks D
    AIDS; 2000 Feb; 14(3):332-3. PubMed ID: 10716516
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pancreatic disease in patients with HIV treated with didanosine (DDI)].
    Ortega González E; Martín Herrera A; López de Medrano V; de Lelis FP; Ronda Gasulla FA; Gil Egea M; Ballester Belda E; Herrera Ballester A
    Rev Esp Enferm Dig; 1996 Feb; 88(2):114-7. PubMed ID: 8664067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.